Science at Asper
The company was established as a spin-off of a scientific institution called the Estonian Biocentre. Initially the idea was to further develop inventions from the Biocentre and from the University. At that time, Asper Biotech did not have access to any technologies for using the innovative APEX genotyping methodology, so everything has been developed from the ground up at Asper Biotech. Our company is always in favor of knowledge transfer, therefore we always work together with the leading experts on particular areas.
During the last 14 years, we have had great relationships with different funding agencies supporting R&D activities, which have eventually led to technological improvements and moreover to state-of-the-art genetic tests. A great example of our collaborations is the participation in numerous European-wide research projects. Our expertise on genetic testing has been widely recognized and incorporated as an essential part of the project.
Our scientists and project managers have worked together with our partners on numerous scientific publications describing new methods, genetic tests and revolutionary results from large scale genetic studies.
Asper Biotech is continuously investing its financial resources and time into innovation, not only regarding new technology development, but rather to a multi-disciplinary approach which integrates technology, medicine and IT.
Anyone interested in further details should feel free to contact Asper Biotech.
Asper Biotech is an appreciated scientific partner in national and international research projects due to its innovation-driven approach and long lasting relationships. The company has been a partner in more than 30 FP6 and FP7 project proposals with 14 having been successfully financed thus far. Membership in FP projects among various international SMEs and Universities has been a great chance to maintain good relationships and find new collaborators all over the world.
FP6 and FP7 projects are run through different consortiums in cooperation with a number of universities, institutes, and SMEs. Asper has communications in Europe, as well as in the USA and Russia. Among our consortium partners are well-known universities and research centers such as Columbia University in the US, the Karolinska Institute in Sweden, the European Genetic Foundation, Pomeranian Medical University and the International Hereditary Cancer Center in Poland, German Cancer Research Center in Heidelberg, Radboud University Nijmegen in the Netherlands, The Cyprus Institute of Neurology and Genetics, University College London, Kings College London, etc.
There is a list of FP6 and FP7 projects with Asper Biotech’s contribution:
FP6 projects: SNP2Chip, ArraySBS, HotSolutes, Mutp53, MedGenet, AO-DNA, Health-e-Child, MolDiagPaca.
FP7 projects: TechGene, Aaveye, GP-TCM, Colorectal cancer testing portfolio, CTCTrap.